November 27, 2015
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...


How Supplied


SIMBRINZA* (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


The recommended dose is one drop of SIMBRINZA in the affected eye(s) three times daily. Shake well before use. SIMBRINZA ophthalmic suspension may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.


Dosage Forms And Strengths

Suspension containing 10 mg/mL brinzolamide and 2 mg/mL brimonidine tartrate.

SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is supplied in white low density polyethylene (LDPE) DROP-TAINER* bottles with a natural LDPE dispensing-tip and light green polypropylene cap as follows:

8 mL in a 10 mL bottle NDC 0065-4147-27

Storage And Handling

Store SIMBRINZA at 2 - 25°C (36 - 77°F).

Alcon Laboratories, Inc., Fort Worth, Texas 76134 USA, 1-800-757-9195, Revised: May 2014

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 11/23/2015

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

WebMD Daily

Get breaking medical news.